Papaverine provides neuroprotection by suppressing neuroinflammation and apoptosis in the traumatic brain injury via RAGE- NF-&lt;kappa&gt;B pathway

Saglam, E. A.; Zırh, Selim; Aktas, Canan Cakir; Müftüoğlu, Sevda; Bilginer, Burçak

doi:10.1016/j.jneuroim.2021.577476

Cited by 8 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…P2ry12 as a microglia marker could be utilized to evaluate the microglial cells. Previous study found that P2ry12 positive microglia were significantly increased after TBI [ 66 ]. However, in this study, we found the P2ry12 expression was decreased after TBI.…”

Section: Discussionmentioning

confidence: 99%

Construction of a lncRNA-associated competing endogenous RNA regulatory network after traumatic brain injury in mouse

Wang

Sun

et al. 2022

Mol Brain

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a major public health problem worldwide which causes high mortality and disability. Functioning as microRNA (miRNA) sponges, long non-coding RNA (lncRNA) regulates the expression of protein-coding genes in a competing endogenous RNA (ceRNA) network. However, the lncRNA-associated ceRNA in TBI remains unclear. In this study, we processed the raw SRR files of mice cortex samples of sham injury (n = 3) and TBI groups (n = 3) to count files. Then, the expression profiles of lncRNAs and mRNAs were identified, and 86 differentially expressed (DE) lncRNAs and 1201 DEmRNAs between sham and TBI groups were identified. The DEmRNAs were used to perform enrichment analyses. Next, a lncRNA-miRNA-mRNA regulatory ceRNA network was constructed. The network consisted of 23 mRNAs, 5 miRNAs and 2 lncRNAs. The expression alternations of the 5 miRNAs were validated via qRT-PCR. The subnetwork of hub lncRNA Neat1 was extracted. We identified a potential inflammatory associated regulatory axis: Neat1/miR-31-5p/Myd88 axis. The PPI network based on DEmRNA involved in ceRNA network was constructed PPI networks to identify the hub genes. Finally, DElncRNAs and DEmRNAs were selected randomly and validated by qRT-PCR. In conclusion, with the lncRNA-miRNA-mRNA ceRNA network provided above, we can improve our understanding of the regulatory mechanisms and interaction among lncRNAs, miRNAs and mRNAs in TBI process.

show abstract

Section: Discussionmentioning

confidence: 99%

Construction of a lncRNA-associated competing endogenous RNA regulatory network after traumatic brain injury in mouse

Wang

Sun

et al. 2022

Mol Brain

View full text Add to dashboard Cite

show abstract

“…Natural remedies like Satureja khuzistanica Jamzad essential oil, rich in carvacrol, have been effective in reducing acute edema and inflammatory responses post-TBI by partially inhibiting NF-κB signaling [74]. Another study demonstrated that papaverine provided neuroprotection by inhibiting receptor for advanced glycation end products (RAGE) and NF-κB signals, resulting in an anti-apoptotic and anti-inflammatory effect, potentially restraining microglial activation after TBI [75].…”

Section: Anti-inflammatory Agents and Immunomodulators In Traumatic B...mentioning

confidence: 99%

Innovative Insights into Traumatic Brain Injuries: Biomarkers and New Pharmacological Targets

Silvestro,

Raffaele,

Quartarone

et al. 2024

IJMS

View full text Add to dashboard Cite

A traumatic brain injury (TBI) is a major health issue affecting many people across the world, causing significant morbidity and mortality. TBIs often have long-lasting effects, disrupting daily life and functionality. They cause two types of damage to the brain: primary and secondary. Secondary damage is particularly critical as it involves complex processes unfolding after the initial injury. These processes can lead to cell damage and death in the brain. Understanding how these processes damage the brain is crucial for finding new treatments. This review examines a wide range of literature from 2021 to 2023, focusing on biomarkers and molecular mechanisms in TBIs to pinpoint therapeutic advancements. Baseline levels of biomarkers, including neurofilament light chain (NF-L), ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1), Tau, and glial fibrillary acidic protein (GFAP) in TBI, have demonstrated prognostic value for cognitive outcomes, laying the groundwork for personalized treatment strategies. In terms of pharmacological progress, the most promising approaches currently target neuroinflammation, oxidative stress, and apoptotic mechanisms. Agents that can modulate these pathways offer the potential to reduce a TBI’s impact and aid in neurological rehabilitation. Future research is poised to refine these therapeutic approaches, potentially revolutionizing TBI treatment.

show abstract

“…In a recent experimental TBI model in mice, single-dose papaverine treatment reduced brain edema, neuroinflammation and apoptosis. Moreover, the administration of papaverine provided microglial inhibition with a decrease in serum S100B levels and showed neuroprotective effects [ 140 ]. Nevertheless, it also has been reported in another study that intraventricular administration of S100B may improve cognitive functions and increase hippocampal synaptogenesis in TBI animals [ 141 ].…”

Section: S100b As a Putative Therapeutic Targetmentioning

confidence: 99%

S100B, Actor and Biomarker of Mild Traumatic Brain Injury

Oris

Kahouadji

Durif³

et al. 2023

IJMS

View full text Add to dashboard Cite

Mild traumatic brain injury (mTBI) accounts for approximately 80% of all TBI cases and is a growing source of morbidity and mortality worldwide. To improve the management of children and adults with mTBI, a series of candidate biomarkers have been investigated in recent years. In this context, the measurement of blood biomarkers in the acute phase after a traumatic event helps reduce unnecessary CT scans and hospitalizations. In athletes, improved management of sports-related concussions is also sought to ensure athletes’ safety. S100B protein has emerged as the most widely studied and used biomarker for clinical decision making in patients with mTBI. In addition to its use as a diagnostic biomarker, S100B plays an active role in the molecular pathogenic processes accompanying acute brain injury. This review describes S100B protein as a diagnostic tool as well as a potential therapeutic target in patients with mTBI.

show abstract

Papaverine provides neuroprotection by suppressing neuroinflammation and apoptosis in the traumatic brain injury via RAGE- NF-<kappa>B pathway

Cited by 8 publications

References 33 publications

Construction of a lncRNA-associated competing endogenous RNA regulatory network after traumatic brain injury in mouse

Construction of a lncRNA-associated competing endogenous RNA regulatory network after traumatic brain injury in mouse

Innovative Insights into Traumatic Brain Injuries: Biomarkers and New Pharmacological Targets

S100B, Actor and Biomarker of Mild Traumatic Brain Injury

Contact Info

Product

Resources

About